drugset / Trial / NCT00940992

A Study of DER 45-EV Gel to Treat Rosacea

NCT00940992 ↗

Phase 2 Completed 92 enrolled Sol-Gel Technologies, Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

To identify lowest efficacious dose of DER 45 EV Gel, 1% and 5% verses vehicle in patients with rosacea.

Timeline

Start
2012-01
Primary completion
2012-09
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DER 45 EV Unknown 1 % Topical
Subject DER 45 EV Unknown 5 % Topical

Indications